HR Execs on the Move

Tetraphase

www.tphase.com

 
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase`s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol `TTPH.` Tetraphase is well positioned to be a major player in the multidrug-resistant arena.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.tphase.com
  • 480 Arsenal Street Suite 110
    Watertown, MA USA 02472
  • Phone: 617.715.3600

Executives

Name Title Contact Details

Similar Companies

OPEN Health

We provide deep scientific knowledge, global understanding and broad expertise to enhance market access and medical communications for improved health outcomes.

Grandview Pharmacy

Grandview Pharmacy is a Connersville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tapimmune Inc

Tapimmune Inc is a Issaquah, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia

Ferring Pharmaceuticals

Ferring Pharmaceuticals, Inc. is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.